{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:20:47Z","timestamp":1776928847696,"version":"3.51.2"},"reference-count":36,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2002,5,14]],"date-time":"2002-05-14T00:00:00Z","timestamp":1021334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The overexpression of HER\u20102\/<jats:italic>neu<\/jats:italic> is found in 20\u201330% of patients with breast carcinoma and is an adverse prognostic factor. HER\u20102 overexpression also has been reported in up to 60% of patients with hormone\u2010refractory prostate carcinoma (HRPC) and was correlated with shortened survival. Trastuzumab (Herceptin\u00ae) is a humanized monoclonal antibody that binds to the HER\u20102 receptor and has antitumor activity in patients with HER\u20102\u2010overexpressing breast carcinoma. The authors report the results of HER\u20102 screening from a Phase II trial of chemotherapy with trastuzumab and docetaxel in patients with HER\u20102\u2010overexpressing prostate carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Archival paraffin embedded tumor tissue was obtained from potentially eligible patients and was screened for HER\u20102 expression by immunohistochemistry (IHC) using a specialized test kit. Shed HER\u20102 antigen in serum also was determined using an enzyme\u2010linked immunosorbent assay (ELISA). HER\u20102 gene amplification was assessed by fluorescent in situ hybridization (FISH). Patients with IHC scores of 2+ or 3+ were considered to have HER\u20102 overexpression and were eligible for the trial. To date, 62 patients with HRPC have been screened.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The median patient age was 72 years, and Gleason scores were &lt; 5 in 1 patient, 5\u20137 in 24 patients, &gt; 7 in 23 patients, and not specified in 14 patients. IHC HER\u20102 expression was 0 in 28 patients, 1+ in 14 patients, 2+ in 4 patients, and 3+ in 1 patient. Fifteen patients had either suboptimal tissue (13 patients) for interpretation or had pending results (2 patients). Therefore, 8% of all patients screened (5 of 62 patients) had HER\u20102 overexpression by IHC. Quantitative ELISA for shed HER\u20102 was available in 32 patients; this level was elevated (&gt; 15 ng\/mL) in only 2 patients, and neither had HER\u20102 expression by IHC. Of the 5 patients with 2+ or 3+ HER\u20102 expression by IHC, none had elevated shed HER\u20102 antigen levels by ELISA. FISH for HER\u20102 amplification was performed on 12 specimens; 5 of these specimens were uninterpretable due to specimen artifact, and none of the remaining 7 specimens had HER\u20102 amplification, defined as a ratio &gt; 1. Patient age and Gleason score were not correlated with HER\u20102 status.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Unlike breast carcinoma and contrary to prior reports, HER\u20102 overexpression by IHC in archival prostate tissue from patients who eventually developed hormone\u2010 refractory disease was infrequent. There did not appear to be any correlation between HER\u20102 overexpression by IHC and shed HER\u20102 antigen levels in serum by ELISA in this tumor type. Whether trastuzumab possesses single\u2010agent activity or modulates chemotherapy response in tumor types other than breast carcinoma remains to be determined. Cancer 2002;94:2584\u20139. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10526<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10526","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T19:28:18Z","timestamp":1030303698000},"page":"2584-2589","source":"Crossref","is-referenced-by-count":47,"title":["HER\u20102\/<i>neu<\/i> is overexpressed infrequently in patients with prostate carcinoma"],"prefix":"10.1002","volume":"94","author":[{"suffix":"Jr.","given":"Primo N.","family":"Lara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick J.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl R.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Gandour Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul H.","family":"Gumerlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caren","family":"Kauderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garrett","family":"Tichauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemyslaw","family":"Twardowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,5,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.52.1.23"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/07357909909011728","article-title":"Treatment options in androgen independent prostate cancer","volume":"17","author":"Lara PN","year":"1998","journal-title":"Cancer Invest"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2992090"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(199602)28:2<73::AID-PROS1>3.0.CO;2-O"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2470152"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2894"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931115)72:10<3020::AID-CNCR2820721026>3.0.CO;2-#"},{"key":"e_1_2_6_9_2","first-page":"5693","article-title":"Amplification and overexpression of HER\u20102\/neu (c\u2010 erbB2) in endometrial cancers: correlation with overall survival","volume":"55","author":"Saffari B","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_6_10_2","first-page":"7811","article-title":"Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients","volume":"50","author":"Ranzani GN","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_6_11_2","first-page":"5675","article-title":"Amplification and overexpression of HER\u20102\/neu in carcinomas of the salivary gland: correlation with poor prognosis","volume":"54","author":"Press MF","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.2940030503"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38356-8"},{"key":"e_1_2_6_14_2","first-page":"A3837","article-title":"Comparison of HER\u20102\/neu in prostate and breast carcinomas","volume":"36","author":"Wright GL","year":"1995","journal-title":"Proc AACR"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.2940050413"},{"key":"e_1_2_6_16_2","first-page":"A463","article-title":"Overexpression of the Her\u20102\/neu receptor tyrosine kinase confers androgen\u2010independent prostate cancer growth","volume":"38","author":"Craft N","year":"1997","journal-title":"Proc AACR"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.23.1918"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2162::AID-CNCR14>3.0.CO;2-U"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990820)84:4<421::AID-IJC16>3.0.CO;2-9"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1302"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(97)90157-X"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1006\/exmp.1999.2242"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.9.1436"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006137619153"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00403-2"},{"key":"e_1_2_6_27_2","first-page":"291","article-title":"The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin\u2122 pivotal trials","volume":"19","author":"Mass RD","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_28_2","first-page":"395","article-title":"Detection of low level HER\u20102\/neu gene amplification in prostate cancer by fluorescent in situ hybridrization (FISH)","volume":"7","author":"Liu HL","year":"2001","journal-title":"Cancer J"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1006\/exmp.1999.2242"},{"key":"e_1_2_6_30_2","first-page":"803","article-title":"Survey of gene amplifications during prostate cancer progression by high\u2010 throughput fluorescence in situ hybridization on tissue microarray","volume":"59","author":"Bubendorf L","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35799-3"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2001.01084.x"},{"key":"e_1_2_6_33_2","first-page":"2432","article-title":"Her 2 expression in prostate cancer","volume":"20","author":"Barrios CH","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_34_2","first-page":"2408","article-title":"Evaluation of HER2 in prostate cancer by immunohistochemistry (IHC) with 2 different antigen retrieval techniques and fluorescent in situ hybridization (FISH)","volume":"20","author":"Sweeney CJ","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.0.CO;2-V"},{"key":"e_1_2_6_36_2","first-page":"1298","article-title":"A Phase II trial of herceptin alone and with taxol for the treatment of prostate cancer","volume":"19","author":"Morris MJ","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_37_2","first-page":"1365","article-title":"HER2 expression in androgen independent prostate cancer","volume":"19","author":"Reese DM","year":"2000","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10526","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:15:58Z","timestamp":1760289358000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10526"}},"subtitle":["Results from the California Cancer Consortium screening trial"],"short-title":[],"issued":{"date-parts":[[2002,5,14]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,5,15]]}},"alternative-id":["10.1002\/cncr.10526"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10526","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,14]]}}}